Oxandrolone


Generic Medicine Info
Contraindications
Known or suspected prostate cancer; breast cancer, nephrosis, hypercalcaemia. Pregnancy.
Special Precautions
Patient w/ risk factors or pre-existing CV disease, COPD, DM, oedematous conditions (e.g. migraine, seizure disorder). Renal and hepatic impairment. Elderly, childn. Lactation. Monitoring Parameters Monitor LFT, lipid profile, Hb, haematocrit; urine and serum Ca levels in women w/ metastatic breast cancer. Assess bone maturation in childn via radiographic examination. Monitor for signs of virilisation in women.
Adverse Reactions
Significant: Blood lipid (e.g. decreased HDL, increased LDL), cholestatic hepatitis, jaundice, hypercalcaemia, carbohydrate intolerance; oedema; risk of CV disease; virilisation (e.g. baldness, clitoral enlargement, deepening of voice, hirsutism, menstrual irregularities); polycythaemia, accelerated bone maturation (childn); prostatic hypertrophy and prostate cancer (elderly). Nervous: Habituation, excitementation, insomnia, depression. Genitourinary: Increased CrCl; erectile dysfunction (e.g. increased or persistent erections), phallic enlargement (prepubertal males); inhibition of testicular function, testicular atrophy, oligospermia, impotence, chronic priapism, epididymitis, irritable bladder (postpubertal males). Hepatic: Increased ALT, AST. Endocrine: Changes in libido, gynaecomastia, increased creatinine phosphokinase (CPK). Haematologic: Prolonged prothrombin time, suppressed clotting factors II, V, VII and X. Musculoskeletal: Premature closure of epiphyses (childn). Dermatologic: Acne vulgaris, androgenic alopecia, hirsutism.
Potentially Fatal: Peliosis hepatis, malignant liver cell tumours. Rarely, hepatic necrosis.
Drug Interactions
Increased risk of bleeding w/ oral anticoagulants (e.g. warfarin). May increase the effects of oral hypoglycaemic agents. Increased risk of oedema w/ corticosteroids and ACTH.
ATC Classification
A14AA08 - oxandrolone ; Belongs to the class of androstan derivative anabolic steroids used as systemic anabolic agents.
Disclaimer: This information is independently developed by CIMS based on oxandrolone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in